Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 55, Issue 7, Pages 3479-3487Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm3001373
Keywords
-
Categories
Funding
- Medicines for Malaria Venture (MMV) [MMV09/0002]
- University of Cape Town
- South African Medical Research Council
- South African Research Chairs initiative of the Department of Science and Technology
Ask authors/readers for more resources
A novel class of orally active antimalarial 3,5-diaryl-2-aminopyridines has been identified from phenotypic whole cell high-throughput screening of a commercially available SoftFocus kinase library. The compounds were evaluated in vitro for their antiplasmodial activity against K1 (chloroquine and drug-resistant strain) and NFS4 (chloroquine-susceptible strain) as well as for their cytotoxicity. Synthesis and structure activity studies identified a number of promising compounds with selective antiplasmodial activity. One of these frontrunner compounds, 15, was equipotent across the two strains (K1 = 25.0 nM, NF54 = 28.0 nM) and superior to chloroquine in the K1 strain (chloroquine IC50 K1 = 194.0 nM). Compound 15 completely cured Plasmodium berghei-infected mice with a single oral dose of 30 mg/kg. Dose response studies generated ED50 and ED90 values of 0.83 and 1.74 mg/kg for IS in the standard four-dose Peters test. Pharmacokinetic studies in the rat indicated that this compound has good oral bioavailability (51% at 20 mg/kg) and a reasonable half-life (t(1/2) similar to 7-8 h).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available